Nouvelle déclaration d'incident
No de la demande: 2017-2159
Numéro de référence du titulaire d'homologation: 2017KP104
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer Inc
Adresse: 2920 matheson BLVD
Ville: Mississaugua
État: ON
Pays: Canada
Code postal /Zip: L4W 5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: UNKNOWN
Inconnu
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-152
Nom du produit: advantage II large cat
Liquide
Oui
Unités: mL
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Cat / Chat
Russian Blue
1
Homme
20
15
lbs
Cutanée
>1 wk <=1 mo / > 1 sem < = 1 mois
>1 wk <=1 mo / > 1 sem < = 1 mois
Système
>1 mo and <= 2mos / >1 mois et < = 2mois
Oui
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On an unspecified date post application, in approximately Feb-2017, the cat exhibited pruritus. On 09-Feb-2017, the owner administered 1 tube of Advantage II Large Cat (Imidacloprid-Pyriproxyfen) topically. Approximately 40 minutes post application, the cat exhibited loose stools, 4 episodes of vomiting, and lethargy. The owner wiped the application site with dish soap and water, but the cat was not examined by a veterinarian and the clinical signs continued. Follow-up received on 24th Mar 2017: On an unknown date in approximately Jan2017, a 20 year old, approximately 15 pound, neutered, male, Russian Blue feline, in unknown condition, with concomitant skin allergies, was administered 1 tube of Advantage II Large Cat (Imidacloprid-Pyriproxyfen) topically by the owner. On an unspecified date post application, in approximately Feb-2017, the cat exhibited pruritus. On 23-Feb-2017, the owner administered 1 tube of Advantage II Large Cat (Imidacloprid-Pyriproxyfen) topically. Approximately 6 hours post application, the cat exhibited loose stools, 4 episodes of vomiting, lethargy, and dilated pupils; the owner washed the application site with dish soap and water. On 24 Feb 2017, the cat exhibited abnormal behavior. The cat was seen by the veterinarian, weighed 7 pounds, was diagnosed with hypertension, and administered intravenous fluids. On 26 Feb 2017, the cat was re-examined by the veterinarian and administered unspecified antibiotic and unspecified blood pressure medication. On approximately 28Feb2017, the feline died; no necropsy was performed.
Mort
Reported pruritus on other than the application site is not anticipated with topical product administration. If any, skin reaction would be localized at the application site. Time to onset unknown. Other causes (concomitant history of skin allergies) should be considered. Later reported loose stools, vomiting, and lethargy are unspecific and may have many potential causes. Time to onset short, though. Oral product uptake was not witnessed. Even with oral product exposure sign would not be expected, but rather salivation. Dilated pupils are not expected with appropriate topical product use. Weight loss, diagnosed hypertension and later reported death are not expected after topical product application as inconsistent with pharmaco-toxicological product profile and experience. Product has wide margin of safety. Oral LD50 in rat is 642 mg/kg BW. 24-fold overdosage tolerated by cats without showing any side effect. The cat was very old (20 years old), thus underlying age-related medical problems are quite likely. Some information (e.g. health status and necropsy results) is not available. Neverthless, considering the products pharmacological profile, a relation is considered unlikely, but due to limited information, the case was considered as unassessable.